Dainippon Sumitomo Receives Approval For Schizophrenia Drug Lonasen
This article was originally published in PharmAsia News
Dainippon Sumitomo received approval for the schizophrenia drug Lonasen (blonanserin) from Japan's Ministry of Health, Labor and Welfare and will launch the product in April 2008. The drug reduces first-stage symptoms such as flashbacks, delusions, and low stamina, and has no weight increase side effects. The Japanese schizophrenia drug market has been rapidly growing; from ¥50 billion in 2000 to ¥100 billion today. (Click here for more-Japanese language
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.